Interleukin 6 (IL-6) is a potent pleiotropic cytokine, known, among others, to stimulate immunoglobulin production by B cells and to trigger acute-phase protein synthesis by hepatocytes. Similar to IL-1, it is produced by monocytes and macrophages following an inlamator challenge. Analysis ofIL-6 receptor (IL-6R) expression on different human cell lines indicates that dexamethasone could upregulate the number of IL-6R on one epithelial cell line (UAC) and on two hepatoma cell lines (HepG2 and Hep3B). This effect was confirmed by Scatchard analysis of binding experiments, using '35S'methionine and [35S~cysteine metabolically labeled IL-6. It was confirmed at the level of mRNA expression by Northern blot analysis. These results provide evidence for a link between IL-6 and glucocorticoids. They could represent an example of a system in which one role of glucocorticoids is to defme more accurately the target of cytokines, and they could explain, at least partly, the frequently observed synergy between IL-6 and glucocorticoids, notably in the case of hepatocytes.
Interleukin 6 (IL-6) is a pleiotropic cytokine (also named B-cell stimulatory factor 2, 26-kDa protein, hybridoma plasmacytoma growth factor, interferon (B2 (IFN- (32) , and heptocyte stimulating factor) produced by a variety of cell types (macrophages, T lymphocytes, endothelial cells, fibroblasts, epithelial cells, astrocytes, keratinocytes and various tumor cells) either constitutively or after induction by different agents such as IL-1, tumor necrosis factor (TNF), poly-(I)-poly(C), viruses, lipopolysaccharide, and platelet-derived growth factor. This cytokine exerts a number of biological activities: it induces (i) terminal differentiation (secretion of immunoglobulins) in B cells; (ii) the growth on various B cells (myeloma/plasmacytoma/hybridoma cells) and EpsteinBarr virus-transformed B-lymphoblastoid cell lines, where it acts as a potent growth factor; (iii) cell growth and cytotoxic T cell differentiation in T cells; (iv) macrophage differentiation; (v) multipotential colony formation of hematopoietic stem cells; (vi) acute-phase protein synthesis by hepatocytes; and (vii) neural differentiation (1, 2) .
These diversified biological activities result from endocrine, paracrine, and perhaps autocrine interactions of the cytokine with various target cells (1) . IL-6 seems to be produced in excess in various pathological conditions such as, for example, rheumatoid arthritis, multiple myeloma, the Lennert syndrome (a histiocytic lymphoma), Castleman disease, and liver cirrhosis (1, 3) . IL-6 is therefore considered one of the major cytokines regulating and coordinating the multiple components of the inflammatory and immune response.
On the other hand, it is apparent that many, if not all, ofthe known cytokines (4) are usually integrated into a vast and intricate network (5, 6) and act in synergy; furthermore, each has a biological activity that is generally shared by several members of the network. The network concept implies coordinated regulation of expression of the various cytokines and their effector genes (7, 8) and also, in some instances, the fine tuning of the expression of their high-affinity specific receptors (9) .
Extensive studies have been made on the molecular mechanisms regulating the expression of interleukin receptors (R). In the case of IL-2R, both the complex underlying molecular mechanisms and biological implications of these regulations have been investigated (9, 10) . Interestingly, IL-2Rs are modulated by and IL-6 (11, 12) . IL-iRs on the other hand are modulated by glucocorticoids (13 180 Al. Thereafter, incubation medium was taken off, and cells were rinsed once with ice-cold culture medium and solubilized in 0.5 ml of 1% SDS/100 mM NaOH. The entire volume was transferred to counting vials, with 10 ml of scintillation medium (Aquasol, NEN) , and counted in a (-counter. Cell-bound radioactivity in the presence of unlabeled IL-6 gave nonspecific binding. Specific binding was calculated by subtracting this value from the total bound radioactivity in the absence ofunlabeled IL-6.
Northern Blot Analysis. The expression of IL-6R mRNA was analyzed by RNA blot hybridization with the human IL-6R cDNA probe. The Xho I firagment of pBSF2R-236 plasmid (16) was used as a template for labeling the DNA by random priming (19) (Multiprime, Amersham) using a-
[32P]dCTP (Amersham). RNA was extracted by two successive cycles of 2 M'LiCl precipitation, after proteinase K digestion of 90-150 x 106 cells (20) . Poly(A)+ RNA was selected by oligo(dT)-cellulose chromatography. Electrophoresis was run on 2% formaldehyde/1% agarose gel, after spectrophotometric determination of the quantity of total mRNA'present in the samples, to allow quantitative comparison of the different blots. Further standardization of the amount of mRNA per lane was obtained by rehybridizing the filters with a rat glyceraldehyde-3-phosphate dehydrogenase cDNA probe and scanning the intensity of a unique 1600-nucleotide band visible in each lane (20) .
RESULTS
Up-Regulation of IL-6R on UAC Cells by Glucocorticoids.
Figs. 1, 2, and 3 show the time kinetics, concentration dependence, and Scatchard analysis of the effect of dexamethasone on IL-6R expression on UAC cells. Induction of IL-6 binding activity became visible after 4 hr and reaches a maximum 10-14 hr after the introduction of dexamethasone in the medium (Fig. 1) . This is in agreement with the kinetics observed at the mRNA level, as we shall discuss later. Fig. 2 To see whether the enhancement of IL-6 binding activity was due to an increase in the number ofbinding sites or rather a change in their affinity, we performed Scatchard analysis of the binding value obtained by progressive saturation of the receptors on UAC cells. The results are presented in Fig. 3 . The data obtained have been analyzed by nonlinear regression using a program especially devised for binding studies by S. Swillens (University of Brussels Medical School). They show that UAC cells express constitutively an average number of700 sites per cell and that this number increases to 1640 receptors per cell after treatment with 0.1 AM dexamethasone for 14 hr. Both curves fit a model defined on the basis of receptors displaying a single high-affinity constant.
The calculated Kd values of the IL-6 binding sites in dexamethasone-treated cells (Kd = 48.5 pM) and in untreated cells (Kd = 34.7 pM) are not significantly different (Fig. 3) . Numerous independent experiments of this type confirmed that dexamethasone induces an increase in the number of binding sites without altering their affinity for the ligand. The number of receptors found per cell was slightly higher than in our previous experiments (17) . This could be due to a better definition of specific radioactivity of the "S-labeled IL-6 and to a better measurement of nonspecific binding in the present study. The Kd values obtained here are consistent with those found for other cells, particularly CESS cells (14) , although there are some differences with Kd values found in studies by others (15) . It was important to check the specificity of the effect of glucocorticoid on IL-6R expression on UAC cells. 
DISCUSSION
Glucocorticoid Up-Regulation ofIL-6R on Human Epithelial Cell Lines. In this study, we describe the up-regulation of IL-6R by glucocorticoid hormones on three cell lines: UAC, HepG2, and Hep3B cells. Of these, one is of amniotic origin (UAC) and two are hepatocyte derived (HepG2 and Hep3B). Thus, there is no apparent link between the first line and the two others, except their epithelial-like type.
The results presented here indicate that glucocorticoids act on IL-6R by stimulating de novo synthesis of the molecule responsible for IL-6 binding activity. Analysis of data obtained by progressive binding saturation shows us that a 16-hr treatment of the cells by glucocorticoids increases the number of IL-6 binding sites by at least 2-fold, without having a detectable effect on their affinity for the cytokine. This modulation seems to be specific for glucocorticoid hormones and occurs at a glucocorticoid concentration consistent with the affinity of the glucocorticoid receptor. It is important to note that dexamethasone concentrations active in the in vitro assay are in the same range as physiological concentrations reached by glucocorticoid hormones in the circulation, although it is somewhat fallacious to compare a natural hormone with its synthetic analog.
Kinetic studies show an optimal IL-6 binding activity between 10 and 14 hr ofglucocorticoid treatment, which could be the time necessary to accumulate a maximal amount of the receptor. mRNA expression reaches a maximum after 6.5 hr, which logically precedes the peak of IL-6R. This suggests an underlying mechanism stimulating the transcription of the receptor mRNA, but we cannot exclude a stabilization of this mRNA or a combination of the two possibilities.
Possible Biological Role of the Modulation of Cytokine
Receptors by Glucocorticoids. Our results could explain, at least partly, the known synergy between glucocorticoids and IL-6 in stimulating synthesis of acute-phase proteins by hepatocytes including the HepG2 and Hep3B hepatoma (24, 25) . Another synergy could be explained by a modulation of cytokine receptors by glucocorticoid. This concerns IL-6, IL-1, and dexamethasone and takes place by B lymphocytes for immunoglobulin production (26) . Glucocorticoids are known to induce IL-1R expression on B cells (13) ; there might be a similar effect for the IL-6R.
The down-regulation by glucocorticoids of cytokine production appears to be a common phenomenon in the biology of the immune and hematopoietic systems. Known examples include TNF (27) , granulocyte-macrophage colony-stimulating factor (28), IL-1 (43, 44) , , and IFN-y (30). IL-6 does not constitute an exception to this rule. For instance, IL-1-stimulated IL-6 mRNA induction is reduced by dexamethasone in fibroblasts (31) and in an astrocytoma cell line (28) . In peripheral blood monocytes, HSFt production is also inhibited by dexamethasone (21) .
IL-1 and TNF stimulated IL-6 secretion on UAC cells and this was down-regulated by dexamethasone too (results not shown). As no IL-6 was produced constitutively by these cells, we are sure that no interference of endogenous IL-6 occurred in our binding assay. The same is true for HepG2 cells (32) .
As far as the expression of cytokine receptors is concerned, glucocorticoids seem to exert a positive influence. This has now been demonstrated for IL-1R on B cells (13) , for IFN-yR on monocytes (33) , and, as we show here, for IL-6R on epithelial cell lines. These regulations are characterized by an increase in the number of binding sites rather than an increase of the receptor affinity, with the exception of TNF receptors, on a murine fibroblast line that is reduced by glucocorticoid (34) . tAlthough IL-6 was not known at that time, most "HSF" activities are accounted for by IL-6 and it is very likely that this previously described "HSF" from monocyte supernatants was in fact IL-6. Proc. Natl. Acad. Sci. USA 87 (1990) Such regulation of cytokines and their receptors by glucocorticoid hormones raises interesting questions, particularly in the case of IL-1 and IL-6. Because both proteins are known to be involved in the stimulation of the hypothalamicpituitary axis, leading to the release of cortisol in the bloodstream by adrenal cells (21) , it has been proposed that their down-regulation by glucocorticoid represents a feedback mechanism preventing excessive production of inflammatory mediators when this takes place following injury or infection.
In this respect, blood leukocytes and cells of the anterior pituitary gland display some similar features. Indeed, they are both able to produce corticotropin activity (35) , and recent observations suggest that certain cells of the anterior pituitary gland share with leukocytes (and many other cell types) the ability to secrete IL-6 (36) .
On the other hand, IL-6, IL-1, and also IL-2 possess corticotropin-releasing hormone activity, triggering the release of corticotropin by the anterior pituitary gland (21, 37, 38) . Others have suggested that IL-1 and IL-6 have a direct action on the secretion of hypothalamic corticotropinreleasing factor (39, 40) .
All these events could contribute to the increased cortisol level observed in acute infections or inflammatory reactions. This could have at least two consequences: first, it would provide a regulatory feedback to prevent an accumulation of cytokines, which could be the source of nondesirable side effects: for example, the susceptibility of LEW/N rats to streptococcal cell wall-induced arthritis is related to a defective hypothalamic pituitary-adrenal axis, with an impaired plasma corticosterone response (41) . Second, glucocorticoid could help to realize a better selection of the target of cytokines. This is probably one of the reasons for the modulatory effects of glucocorticoid hormones observed on cytokine receptors.
We cannot exclude the fact that other intracellular proteins that participate in the transmission ofthe signal given by are also modulated by dexamethasone. Nevertheless, we consider that the modulation of IL-6R by glucocorticoid constitutes a first step in the explanation of the synergy between dexamethasone and IL-6 in stimulating hepatocytes, and maybe other cell types in the human body.
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